Taken together, these novel findings suggest that combination of TMZ-mediated chemotherapy with inhibition of the WNK1/OSR1/NKCC1 signaling pathway presents a new strategy for improving glioma treatment. The gene discussed is SLC12A2; the disease is glioma.